Hengrui Pharmaceuticals

Explore the latest insights on Hengrui Pharmaceuticals and its impact on China’s pharmaceutical industry. Fineline Info & Tech delivers reliable data, news, and intelligence to help you navigate the complexities of Hengrui Pharmaceuticals’s developments with precision and clarity. Stay informed and enhance your decision-making at flcube.com.Explore the latest insights on Hengrui Pharmaceuticals and its impact on China's pharmaceutical industry. Fineline Info & Tech delivers reliable data, news, and intelligence to help you navigate the complexities of Hengrui Pharmaceuticals's developments with precision and clarity. Stay informed and enhance your decision-making at flcube.com.

Patronus Biotech Secures Ethics Approval to Launch Phase I Trials of Three Multi‑Stage U‑VLP Malaria Vaccine Candidates – First‑in‑Human Study of LYB014, LYB017 and LYB027 Set to Begin in Australia
CompanyDrug

Patronus Biotech Secures Ethics Approval to Launch Phase I Trials of Three Multi‑Stage U‑VLP Malaria Vaccine Candidates – First‑in‑Human Study of LYB014, LYB017 and LYB027 Set to Begin in Australia

Patronus Biotech Co., Ltd. announced that its three multi‑stage novel U‑VLP malaria vaccine candidates – LYB014, LYB017 and LYB027 – have been approved by the Bellberry Human Research Ethics Committee…

Takeda's Adcetris Approved by NMPA for First-Line CD30-Positive PTCL – China's First and Only Targeted Therapy in Combination With CHP for sALCL and Other CD30-Positive Peripheral T-Cell Lymphomas

Takeda’s Adcetris Approved by NMPA for First-Line CD30-Positive PTCL – China’s First and Only Targeted Therapy in Combination With CHP for sALCL and Other CD30-Positive Peripheral T-Cell Lymphomas

NMPA Approves New Indication for J&J's Tecvayli in Relapsed or Refractory Multiple Myeloma – Bispecific BCMA/CD3 Antibody Moves to First Relapse After ≥1 Prior Line

NMPA Approves New Indication for J&J’s Tecvayli in Relapsed or Refractory Multiple Myeloma – Bispecific BCMA/CD3 Antibody Moves to First Relapse After ≥1 Prior Line

Empowering Chinese Pharma’s Global Expansion

Leverage premier media reach to connect your pipeline with global partners. Contact us to drive your international growth today.
Explore Now
CompanyDrug

Hengrui Pharmaceuticals Secures NMPA Breakthrough Therapy Designation for HRS-7058 in KRAS G12C-Mutant Pancreatic Cancer

CompanyDrug

Hengrui Pharmaceuticals Secures NMPA Clinical Approval for First-in-Class SHR-4685 in Advanced Solid Tumors

CompanyDrug

Hengrui Pharmaceuticals Secures NMPA Priority Review for Trastuzumab Rezetecan in HER2-Low Breast Cancer, Expanding Third Indication in China

CompanyDrug

Hengrui Pharmaceuticals Secures NMPA Priority Review for Trastuzumab Rezetecan in HER2-Low Breast Cancer, Expanding Third Indication in China

CompanyDrug

Hengrui’s Rezvilutamide Receives EMA Acceptance for Metastatic Prostate Cancer Treatment

CompanyDrug

Hengrui Pharmaceuticals Expands Dalpiciclib Label with NMPA Approval for Early Breast Cancer Adjuvant Therapy

CompanyDrug

Hengrui Pharmaceuticals Receives NMPA Clinical Approvals for Two Novel Anti-Tumor Candidates SHR-6914 and HRS-7525, Addressing Unmet Needs in Prostate Cancer and Solid Tumors

CompanyDrug

Hengrui Pharmaceuticals Advances Triple-Asset Breast Cancer Strategy with NMPA Approval for HRS-6209 Combination Study, Leveraging Selective CDK4 Inhibitor and Novel SERD

Show More